กำลังโหลด
NASDAQHealthcareBiotechnology
ข้อมูลล่าสุด
US$11.61
+US$1.61 · +16.10%
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
ราคาปิดก่อนหน้า
US$11.61
+US$1.61 · +16.10%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$11.61
ช่วง 52 สัปดาห์
ปัจจุบัน US$11.61
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$11.61
ช่วง 52 สัปดาห์
ปัจจุบัน US$11.61
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI18.18M0.00%2.3T USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB13.14M0.01%185.3B USD0.03%US$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI12.38M0.13%9.87B USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM12.2M0.02%78.27B USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK7.5M0.02%44.7B USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF7.42M0.01%95.4B USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO4.09M0.02%18B USD0.06%US$112.66+0.50%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM3.03M5.48%55.29M USD0.59%US$29.6009+1.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWORoundhill Investments - GLP-1 & Weight Loss ETFOZEMเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
